- Join Biopharma Holdings Limited CNTB announced topline results for the primary analysis population of the pivotal study of CBP-201 in patients with moderate to severe atopic dermatitis (AD) in China.
- This study evaluates the efficacy and safety of CBP-201 and the potential for an extended CBP-201 dosing interval during the maintenance phase of treatment.
- The primary IGA endpoint of 0 or 1 (“clear” or “almost clear”) with at least 2 degrees of reduction from baseline at week 16 was significantly higher for the CBP-201 group (300 mg every other week) at 30.3 % of patients showed an improvement compared to 7.5% in the placebo group.
- Related: Connect Biopharma’s candidate for skin disease-related pruritus shows an encouraging safety profile.
- Significant improvement in pruritus, with 35.0% of patients experiencing a reduction of 4 or more on the Peak Pruritus-Numerical Rating Scale (PP-NRS) compared to 9.6% with placebo.
- CBP-201 was generally well tolerated, with safety results comparable to placebo.
- Price promotion: CNTB shares are down 0.95% to $1.2975 on Tuesday’s latest check.
© 2022 Benzinga.de. Benzinga does not provide investment advice. All rights reserved.
